SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

PLRX

Pliant Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor FORTIFY interim data expected in 2027 and further preclinical data on the RNAi delivery platform. The cash runway to mid-2028 provides a long development horizon, but the EPS miss and zero revenue keep the stock dependent on clinical catalysts.

DirectionNeutral
Confidencehigh
Horizonmonths

PLN-101095

● Neutral Named in this press release
Impact
Phase
Phase 1b
Time to market
At least 3-5 years away, if ever. The drug is still in Phase 1b testing. Even under a Fast Track pathway, it would need to complete Phase 2 and Phase 3 trials before any approval filing.
Next catalyst
None dated

What to watchPLN-101095 is an early-stage oncology asset at a cash-strapped company that already lost its lead pipeline drug. Watch for FORTIFY enrollment completion updates and any efficacy signals from the Phase 1b expansion cohorts. The stock is trading near cash value, so positive data could drive a meaningful rally, but the company's financial runway and lack of analyst coverage are serious headwinds. No near-term binary catalyst is on the calendar.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.6970
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.55%
T+1 · $0.6932
Vs SPY
+1.37%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.6970entry
  2. T+1 · 20h ago −0.55%α +1.37% · $0.6932
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pliant Therapeutics reported Q3 2026 net loss of $24.4M ($0.39 per share), slightly narrower than the $26.3M loss a year ago, while revenue remained zero. The company highlighted strong enrollment in its FORTIFY Phase 1b trial for PLN-101095 and initial preclinical data for its integrin-mediated drug delivery platform. With $142.6M in cash, operations are funded to mid-2028, but the stock's $49M market cap reflects the high-risk, pre-revenue stage.

Key Financial Metrics

EPS
−$0.39
est −$0.37 · -5.4%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Net loss of $24.4M for Q3 2026 vs $26.3M in Q3 2025
  • EPS of $(0.39) vs consensus $(0.37), a miss of 5.4%
  • Revenue was $0 (pre-revenue clinical-stage biotech)
  • Cash, cash equivalents and short-term investments of $142.6M, sufficient to mid-2028
  • FORTIFY Phase 1b trial for PLN-101095 enrolling ahead of schedule; interim data expected in 2027
  • Preclinical data for integrin-mediated drug delivery platform showed >75% target gene knockdown in non-human primates

Financial Impact

Net loss of $24.4M, EPS miss of $0.02 vs consensus; cash burn rate implies ~$97M annual operating cash use

net lossepscash position

Risk Factors

  • EPS miss of 5.4% vs consensus may pressure the stock near-term
  • Pre-revenue stage with no approved products; all value depends on clinical trial success
  • Cash burn rate of ~$24M/quarter implies ~6 quarters of runway; dilution risk if capital needs arise
  • FORTIFY trial enrollment ahead of schedule but interim data not expected until 2027

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402173

Track record

8 reports on PLRX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +11.02% at T+60 after the May 11, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
  2. Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
  3. May 11, 202627w ago 8-K Neutral 4/10 No price data
  4. May 11, 202627w ago Press Release Bearish 6/10 Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
  5. Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
  6. Apr 7, 202632w ago EFFECT Neutral 4/10 Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
  7. Mar 11, 202635w ago 8-K Bullish 7/10 Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
  8. Mar 3, 202636w ago 8-K Neutral 3/10 Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026